Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Meadowsweet (Filipendula ulmaria) contains salicylates, flavonoids, and tannins. It is used as a natural anti-inflammatory and antacid for gastritis and peptic ulcer. The salicylate content creates similar interactions to aspirin: avoid with anticoagulants (warfarin, aspirin), NSAIDs, and in aspirin-sensitive individuals. Avoid in children under 16 (Reye’s syndrome risk from salicylates). Do not use in pregnancy. Contraindicated in aspirin allergy.
Biological and Chemical Classification
- Scientific Name
- Filipendula ulmaria
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Meadowsweet indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 01 მაი 2026, 18:08
Evidence Distribution
-
Observational / other LOW evidence YELLOWCharacterization and Biological Activity of Rutin Extracted from Filipendula ulmaria (L.) Maxim. ↗Vesnina A et al.. Characterization and Biological Activity of Rutin Extracted from Filipendula ulmaria (L.) Maxim.. BioTech (Basel). 2026. PMID:41892152.PMID 41892152 ↗Journal BioTech (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41892152/
-
Observational / other LOW evidence YELLOWMiquelianin and spiraeoside from Filipendula ulmaria mitigate α-synuclein accumulation in C.elegans and reduce the expression of neuroinflammatory cytokines in human microglia. ↗Redl M et al.. Miquelianin and spiraeoside from Filipendula ulmaria mitigate α-synuclein accumulation in C.elegans and reduce the expression of neuroinflammatory cytokines in human microglia.. Front Pharmacol. 2025. PMID:41756116.PMID 41756116 ↗Journal Front PharmacolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41756116/
-
Observational / other LOW evidence YELLOWLong-range pollen transport across the North Sea: Insights from migratory hoverflies landing on a remote oil rig. ↗Doyle TD et al.. Long-range pollen transport across the North Sea: Insights from migratory hoverflies landing on a remote oil rig.. J Anim Ecol. 2025. PMID:40963187.PMID 40963187 ↗Journal J Anim EcolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40963187/
-
Observational / other LOW evidence YELLOWBroad-Spectrum Antimicrobial Potential of the γ-Core Motif Peptides of Filipendula ulmaria for Practical Applications in Agriculture and Medicine. ↗Slezina MP et al.. Broad-Spectrum Antimicrobial Potential of the γ-Core Motif Peptides of Filipendula ulmaria for Practical Applications in Agriculture and Medicine.. Int J Mol Sci. 2025. PMID:40869280.PMID 40869280 ↗Journal Int J Mol SciYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40869280/
-
Observational / other LOW evidence YELLOWBioindication of radioactive contamination by honey bees in the Bryansk and Rostov regions: Foraging dynamics of (137)Cs and (40)K in the plant-bee-bee… ↗Sorokin PG. Bioindication of radioactive contamination by honey bees in the Bryansk and Rostov regions: Foraging dynamics of (137)Cs and (40)K in the plant-bee-bee product pathway.. Appl Radiat Isot. 2025. PMID:40876308.PMID 40876308 ↗Journal Appl Radiat IsotYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40876308/
-
Observational / other LOW evidence YELLOWUntangling host specialization in a "double dark taxa" system. ↗Awad J et al.. Untangling host specialization in a "double dark taxa" system.. Ann Entomol Soc Am. 2025. PMID:40415972.PMID 40415972 ↗Journal Ann Entomol Soc AmYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40415972/
-
Observational / other LOW evidence YELLOWGreen-Synthesized Silver Nanoparticles Using Filipendula ulmaria (L.) Maxim. and Salvia verticillata L. Extracts Inhibit Migration and Modulate Redox Homeostasis in Human Breast… ↗Matić M et al.. Green-Synthesized Silver Nanoparticles Using Filipendula ulmaria (L.) Maxim. and Salvia verticillata L. Extracts Inhibit Migration and Modulate Redox Homeostasis in Human Breast Cancer Cells via Nrf-2 Signaling Pathway.. Antioxidants (Basel). 2025. PMID:40298802.PMID 40298802 ↗Journal Antioxidants (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40298802/
-
Observational / other LOW evidence YELLOWDNA-Protective, Antioxidant and Anti-Carcinogenic Potential of Meadowsweet (Filipendula ulmaria) Dry Tincture. ↗Andonova T et al.. DNA-Protective, Antioxidant and Anti-Carcinogenic Potential of Meadowsweet (Filipendula ulmaria) Dry Tincture.. Antioxidants (Basel). 2024. PMID:39456454.PMID 39456454 ↗Journal Antioxidants (Basel)Year 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39456454/
-
Observational / other LOW evidence YELLOWEnhancing nitrogen removal through macrophyte harvest and installation of woodchips-based floating beds in surface-flow constructed wetlands. ↗Choudhury MI et al.. Enhancing nitrogen removal through macrophyte harvest and installation of woodchips-based floating beds in surface-flow constructed wetlands.. Chemosphere. 2024. PMID:38719124.PMID 38719124 ↗Journal ChemosphereYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38719124/
-
Observational / other LOW evidence YELLOWTranscriptome-Wide Identification and Expression Analysis of Genes Encoding Defense-Related Peptides of Filipendula ulmaria in Response to Bipolaris sorokiniana Infection. ↗Istomina EA et al.. Transcriptome-Wide Identification and Expression Analysis of Genes Encoding Defense-Related Peptides of Filipendula ulmaria in Response to Bipolaris sorokiniana Infection.. J Fungi (Basel). 2024. PMID:38667929.PMID 38667929 ↗Journal J Fungi (Basel)Year 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38667929/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Meadowsweet. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Meadowsweet
A score of 3.5 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.